Skip to main content


You are viewing the new article page. Let us know what you think. Return to old version

Volume 9 Supplement 2

AIDS Vaccine 2012

Poster presentation | Open | Published:

Targeting HIV Gag p24 to DICR on dendritic cells induces T cell and potent and long-lasting antibody responses in non-human primates


Targeting Dendritic Cells (DCs) with anti-DC receptor antibody-antigen fusion proteins is a novel approach in vaccine development for inducing potent humoral and cellular immune responses.


We engineered an anti-human DCIR recombinant antibody cross-reacting with the cynomolgus macaque receptor fused via the heavy chain C-terminus to HIV-1 Gagp24 protein (anti-DCIR.Gagp24). HIV patient PBMC cultures were incubated with anti-DCIR and control hIgG4.Gagp24 fusion proteins. After 10 days, the total T cells were challenged with HIV Gagp24 peptide pools, and then antigen-specific cytokine production was detected using intracellular staining. Macaques were also immunized i.d. 3 times with anti-DCIR.Gagp24 or control hIgG4.Gagp24 with or without polyI:C. Gagp24-specific IgG titers from serum were measured by ELISA and the magnitude of the antigen-specific IFNγ responses was assessed by ELISPOT.


In vitro, low doses of anti-DCIR Gagp24 prototype vaccine, but not the control hIgG4.Gagp24, expand of Gagp24-specific T cells. These in vitro-expanded antigen-specific T cells were multifunctional, simultaneously producing multiple cytokines (IFNγ, TNFα and MIP-1β). In vivo, in non-adjuvanted naïve animals, serum anti-Gagp24 antibodies were detectable 2 weeks after priming and titers were substantially increased after the 1st and the 2nd boost with anti-DCIR.Gagp24 and were durable, while in the control hIgG4.Gagp24 group the responses were minimal. Poly I:C increased the magnitude of the responses in the anti-DCIR.Gagp24 and hIgG4.Gagp24 groups to a similar level in both groups. T cell responses induced by anti-DCIR Gagp24 could be enhanced after priming with a recombinant modified vaccinia virus Ankara (MVA) encoding HIV Gag/Pol/Nef. Boosting with anti-DCIR.Gagp24 plus poly I:C generated high titers of anti-Gagp24 antibody titers and strongly enhanced IFNγ-producing T cells following priming with MVA HIV Gag/Pol/Nef.


Our results demonstrate that heterologous prime-boost immunization with vectors and DC-targeting protein-based vaccines is a promising vaccination approach to optimize humoral and cellular immunity for therapeutic and preventive applications against AIDS.

Author information

Correspondence to A Flamar.

Rights and permissions

Reprints and Permissions

About this article


  • Vaccinia
  • Peptide Pool
  • Modify Vaccinia Virus Ankara
  • PBMC Culture
  • Preventive Application